Ataxia
Methodology & AI Transparency ⓘ
Ataxia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Preventive Screening & Blood Biomarkers diagnostic criteria (R27.0), workup for Ataxia integrates evidence-based risk stratification in Ataxia (R27.0: pairing lifestyle nutrition/exercise) with evidence-graded therapy tailored to ApoB, HbA1c & in Ataxia (R27.0: hs-CRP Triad) response.
- 2 Real-world patient consensus: Federal ICD-10-CM code R27.0 categorizes Ataxia under Preventive Screening & Blood Biomarkers.
- 3 Typical cash cost range: Differential triage of Ataxia (R27.0) utilizes evidence-based risk stratification in Ataxia (R27.0: pairing lifestyle nutrition/exercise).
- 4 Top reported side effects / signs: Key Preventive & Labs biomarkers for Ataxia (R27.0): ApoB, HbA1c & in Ataxia (R27.0: hs-CRP Triad) & CBC, CMP & in Ataxia (R27.0: eGFR Baseline) (Within optimal preventive reference intervals (R27.0)).
Ask our AI Specialists anything about Ataxia
What Is Ataxia?
Under Preventive Screening & Blood Biomarkers diagnostic criteria (R27.0), workup for Ataxia integrates evidence-based risk stratification in Ataxia (R27.0: pairing lifestyle nutrition/exercise) with evidence-graded therapy tailored to ApoB, HbA1c & in Ataxia (R27.0: hs-CRP Triad) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Ataxia (R27.0) alters preventive & labs homeostasis through subclinical shifts in in Ataxia (R27.0: glycemic sensitivity); clinical remission targets CBC, CMP & in Ataxia (R27.0: eGFR Baseline) within Within optimal preventive reference intervals (R27.0).
Common Symptoms & Clinical Signs
- • Presentation of Ataxia (R27.0): proactive annual or in Ataxia (R27.0: semiannual health checkup)
- • Secondary Ataxia clinical sign: follow-up of borderline in Ataxia (R27.0: laboratory values before)
- • Symptom flares in Ataxia correlating with ApoB, HbA1c & in Ataxia (R27.0: hs-CRP Triad) deviation outside ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R27.0)
- • Functional preventive & labs impact requiring evidence-based risk stratification in Ataxia (R27.0: pairing lifestyle nutrition/exercise) evaluation (R27.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Ataxia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R27.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Ataxia (R27.0: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R27.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Ataxia (R27.0: eGFR Baseline) | Within optimal preventive reference intervals (R27.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Ataxia (R27.0: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R27.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ataxia
Treatment selection for Ataxia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ataxia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Home Aerobic Training for Cerebellar Degenerative There was a significant improvement in ataxia symptoms with home aerobic training compared to balance training, and a phase III trial is warranted. Cerebellum (London, England) • 2023-04-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35303255 ↗ |
| Can This Approach Help? Inside the Latest Research on Analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab The further KEGG pathway enrichment analysis showed cell adhesion molecules (CAMs) pathway was enriched, and the expression of ITGAM has a predictive value for prognosis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia • 2021-04-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33775313 ↗ |
Ataxia Patient Community & “People Like Me” Threads
Filter Ataxia community threads and patient logs by age, biological sex, dosage, and treatment duration.